Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Aletekitug (GSK1070806)
Aletekitug · 2 trials · 1 indication
Adverse events will be collected.
Serious AEs will be collected.
Participants who discontinue study intervention due to AEs will be reported.
Hematology, clinical chemistry, and urinalysis will be collected.
Blood pressure, temperature and pulse rate readings will be collected.
ECG readings will be collected.
| Arm | Type | Description |
|---|---|---|
| Aletekitug | EXPERIMENTAL | Participants will receive Aletekitug. |
| Aletekitug (GSK1070806) | EXPERIMENTAL | Participants will receive Aletekitug. |
| Name | Type | Description |
|---|---|---|
| Aletekitug (GSK1070806) | BIOLOGICAL | Aletekitug will be administered. |
| Aletekitug | BIOLOGICAL | Aletekitug will be administered. |
Inclusion Criteria: * Diagnosis of UC for greater than or equal (\>=) 3 months before screening. Appropriate documentation of endoscopy and biopsy results consistent with the diagnosis of UC, in the assessment of the investigator, must be available. * Active UC with a modified Mayo score (mMS) of 5...
Aletekitug is an investigational monoclonal antibody being developed for the treatment of ulcerative colitis, specifically moderate to severe cases. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Aletekitug is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The drug is in early-stage clinical trials for ulcerative colitis.
Aletekitug is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for any use. Two Phase 1 trials are planned but have not yet started recruiting participants.
Aletekitug is involved in two Phase 1 trials: NCT07747467, a study of multiple interventions in moderate to severe ulcerative colitis, and NCT07747480, a substudy focusing on Aletekitug alone. Both trials are not yet recruiting and each plans to enroll 16 participants.
Yes, Aletekitug is also known as GSK1070806. Both names refer to the same investigational monoclonal antibody being studied for ulcerative colitis.